This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Daiichi Sankyo Company, Limited. Active years: 2019-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Haryana, IN (2019)
- Shinagawa-ku, JP (2020)
Company Filing History:
Years Active: 2019-2020
Title: Innovations of Sagar Ramdas Amale
Introduction
Sagar Ramdas Amale is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds with therapeutic applications. With a total of 2 patents, his work focuses on innovative drug substances that exhibit advantageous characteristics.
Latest Patents
One of his latest patents involves the creation of crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6-(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and its pharmaceutically acceptable salt. This invention provides novel crystals that are excellent in stability and possess satisfactory physical properties as a drug substance. Another significant patent relates to 6-morpholinyl-2-pyrazolyl-9H-purine derivatives, which serve as inhibitors of phosphatidylinositol-3-kinase (PI3K). These compounds can be utilized for treating or preventing various diseases, including inflammatory and autoimmune disorders.
Career Highlights
Sagar Ramdas Amale is currently employed at Daiichi Sankyo Company, Limited, where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing effective treatments that address critical health issues.
Collaborations
He collaborates with talented coworkers, including Priyanka Patel and Yogesh Baban Surase, to advance their research and development efforts.
Conclusion
Sagar Ramdas Amale's contributions to pharmaceutical innovations highlight his role as a key inventor in the industry. His patents reflect a dedication to improving drug efficacy and stability, ultimately benefiting patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
